305 related articles for article (PubMed ID: 17385948)
1. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
Keating GM; Scott LJ
Drugs; 2007; 67(5):793-804. PubMed ID: 17385948
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid for Paget's disease of bone.
Maricic M
Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
[TBL] [Abstract][Full Text] [Related]
3. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
4. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
Krane SM
Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
[No Abstract] [Full Text] [Related]
5. Persistent effect of zoledronic acid in Paget's disease.
Tziomalos K; Florentin M; Krikis N; Perifanis V; Karagiannis A; Harsoulis F
Clin Exp Rheumatol; 2007; 25(3):464-6. PubMed ID: 17631747
[TBL] [Abstract][Full Text] [Related]
6. The use of zoledronic acid for Paget's disease of bone.
Maricic M
Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
[TBL] [Abstract][Full Text] [Related]
7. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.
Gennari L; Merlotti D; Mossetti G; Rendina D; De Paola V; Martini G; Nuti R
Mini Rev Med Chem; 2009 Aug; 9(9):1052-63. PubMed ID: 19689402
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of Paget's disease of bone with zoledronic acid].
Body JJ; Sternon J
Rev Med Brux; 2005; 26(6):513-7. PubMed ID: 16454155
[TBL] [Abstract][Full Text] [Related]
10. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
[TBL] [Abstract][Full Text] [Related]
11. Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid.
Devogelaer JP; Geusens P; Daci E; Gielen E; Denhaerynck K; Macdonald K; Hermans C; Vancayzeele S; Abraham I; Boonen S
Calcif Tissue Int; 2014 Mar; 94(3):311-8. PubMed ID: 24271562
[TBL] [Abstract][Full Text] [Related]
12. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
Reid IR; Lyles K; Su G; Brown JP; Walsh JP; del Pino-Montes J; Miller PD; Fraser WD; Cafoncelli S; Bucci-Rechtweg C; Hosking DJ
J Bone Miner Res; 2011 Sep; 26(9):2261-70. PubMed ID: 21638319
[TBL] [Abstract][Full Text] [Related]
13. Acute myopericarditis following intravenous zoledronic acid for the treatment of Paget's disease.
Watts MR; Ellims AH; Eccleston DS
Med J Aust; 2014 Feb; 200(3):150. PubMed ID: 24528425
[No Abstract] [Full Text] [Related]
14. [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].
Conesa Mateos A; Rotés Sala D; Almirall Bernabé M; Carbonell Abelló J
Med Clin (Barc); 2006 Oct; 127(16):635-6. PubMed ID: 17145033
[No Abstract] [Full Text] [Related]
15. Zoledronic acid for treatment of Paget's disease of bone.
Devogelaer JP; Manicourt DH
Expert Opin Pharmacother; 2007 Nov; 8(16):2863-9. PubMed ID: 17956205
[TBL] [Abstract][Full Text] [Related]
16. [Effect of a single dose of zoledronic acid in a case of Paget bone disease].
Saban M; Fidalgo S; Díaz CA; Lutfi RJ
Medicina (B Aires); 2010; 70(5):445-8. PubMed ID: 20920964
[TBL] [Abstract][Full Text] [Related]
17. Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone.
Polyzos SA
Clin Rheumatol; 2011 Jan; 30(1):149-50. PubMed ID: 21053036
[No Abstract] [Full Text] [Related]
18. [Treatment of Paget's disease of bone: importance of the zoledronic acid].
Griz L; Colares V; Bandeira F
Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):845-51. PubMed ID: 17160207
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological therapy of Paget's and other metabolic bone diseases.
Hosking D
Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
[TBL] [Abstract][Full Text] [Related]
20. Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
Polyzos SA; Anastasilakis AD; Anagnostis P; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
Endokrynol Pol; 2012; 63(4):312-5. PubMed ID: 22933168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]